---
title: Hematology/Oncology
icon: fontawesome/solid/biohazard
author: J. Austin Straley, DO
date: 2024-03-16
permalink: /heme-onc
categories:
    - Hematology
    - Oncology
---
- Anemia
    - Anemia of Chronic Disease
        - [Advancements in anemias related to chronic conditions](https://pubmed.ncbi.nlm.nih.gov/20618092/){:target="_blank"}
    - Transfusion thresholds
        - [TRICC: Better survival in critically ill with Hgb target of >7 than >10](https://pubmed.ncbi.nlm.nih.gov/9971864/){:target="_blank"}
        - [TRISS: Similar mortality with Hgb target of >7 than >9 in septic shock](https://pubmed.ncbi.nlm.nih.gov/25270275/){:target="_blank"}
- Breast Cancer
    - [ATLAS: In ER+ BC, tamoxifen for 10 years reduced recurrence/mortality, increased endometrial cancer and PE risk](https://pubmed.ncbi.nlm.nih.gov/23219286/){:target="_blank"}
- Chronic Leukemia
    - CLL
        - [Ibrutinib-Rituximab > FCR if <70 y/o and untreated](https://pubmed.ncbi.nlm.nih.gov/31365801/){:target="_blank"}
    - CML
        - [IRIS: Imantinib > IFNa/cytarabine in delaying disease progression](https://pubmed.ncbi.nlm.nih.gov/12637609/){:target="_blank"}
- DIC
- General
    - [Multiple CTs increase risk of leukemia and brain tumors](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60815-0/fulltext/){:target="_blank"}
- Iron Deficiency Anemia
    - [Consensus Statement on Peri-operative management of Anemia and IDA](https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.13773/){:target="_blank"}
    - [IRONMAN: IV Iron not better than placebo, did not change # of pRBC transfusion during stay](https://pubmed.ncbi.nlm.nih.gov/27686346/){:target="_blank"}
- Lymphomas
- Thrombocytopenia
    - [EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact](https://pubmed.ncbi.nlm.nih.gov/22868791/){:target="_blank"}
    - [Drug-induced thrombocytopenia](https://pubmed.ncbi.nlm.nih.gov/20008194/){:target="_blank"}
        - [PubMed](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413903/){:target="_blank"}
- VTE
    - [SOME: Not better to screen for occult malignancy in first unprovoked VTE](https://www.nejm.org/doi/full/10.1056/NEJMoa1506623/){:target="_blank"}
    - [AMPLIFY: Oral Apixaban for the Treatment of Acute VTE](https://www.nejm.org/doi/full/10.1056/NEJMoa1302507/){:target="_blank"}
    - PE
        - [Causes of Elevated D-Dimer](https://www.njmonline.nl/article_ft.php?a=1790&d=1189&i=201){:target="_blank"}
        - [ADJUST-PE: Age-adjusted D-Dimer (Age x 10) in patients >50 r/o more pts](https://pubmed.ncbi.nlm.nih.gov/24643601/){:target="_blank"}
        - [ERC/PROPER: Low suspicion and PERC(-) reduces VTE probability to <2%](https://pubmed.ncbi.nlm.nih.gov/18318689/){:target="_blank"}
            - [Also](https://pubmed.ncbi.nlm.nih.gov/29450523/){:target="_blank"}
        - [PIOPED II: CTA is sensitive (90%) and specific (95%) for PE](https://pubmed.ncbi.nlm.nih.gov/16738268/){:target="_blank"}
    - DVT
        - Wells DVT Criteria
            - [Rule-Out with Negative D-Dimer](https://www.nejm.org/doi/full/10.1056/NEJMoa023153/){:target="_blank"}
            - [Diagnosis/Treatment](https://pubmed.ncbi.nlm.nih.gov/17060659/){:target="_blank"}
            - [Treatment](https://pubmed.ncbi.nlm.nih.gov/22315257/){:target="_blank"}
        - CLOT: Dalteparin > Warfarin in preventing recurrent VTE of malignancy


# Oncology
- Breast Cancer
- Chemotherapy
    - General
        - Increased risk of MDS, Mixed MDS/MPN, and AML (10-20% of all cases of these cancers are chemotherapy related)
            - [Therapy-Related Myeloid Leukemia](https://pubmed.ncbi.nlm.nih.gov/18692692/){:target="_blank"}
            - [Etiology and management of therapy-related myeloid leukemia](https://pubmed.ncbi.nlm.nih.gov/18024664/){:target="_blank"}
    - Common Regimens
        - ABVD
            - Adriamycin, Bleomycin, Vinblastine, Dacarbazine
            - Hodgkin Lymphoma
        - BEACOPP
            - Bleomycin, Etoposide, Adriamycin/doxorubicin, Cyclophosphamide, Oncovorin/vincristine, Procarbazine, Prednisone
            - Hodgkin Lymphoma
        - FOLFIRI
            - Leucovorin, 5-Fluorouracil, Irinotecan
            - Advanced-stage and Metastatic Colorectal Cancer
        - FOLFOX
            - Leucovorin, 5-Fluorouracil, Oxaliplatin
        - R-CHOP
            - Rituximab, Cyclophosphamide, Hydroxy-doxorubicin, Oncovorin/Vincristine, Prednisone